... smh
Patients that received TVEC = 291
Responders (CR/PR) to TVEC = 78
54% of responders had confirmed pseudoprogression
78 x 0.54 = 42 patients
42 / 291 = 14.5% pseudoprogression rate
What exactly is the strong point you are trying to make?
The P1 CF33 basket trial has a range of different cancers. The P3 TVEC trial only used melanoma in 300 patients with almost 50% being the first line therapy. The immunotherapy data is obviously the safer comparison because there are significantly more patients (3400) and a variety of cancer types. Even if you compare to TVEC, pseudoprogression rates are significantly lower for CF33 indicating a lack of efficacy.
Ann: Imugene Presentation to Bell Potter Conference, page-76
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |